Janus Henderson Group
IMMX icon

Janus Henderson Group’s Immix Biopharma IMMX Stock Holding History

Janus Henderson Group’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.7M Buy
4,802,002
+880,434
+22% +$6.47M 0.02% 440
2025
Q4 		$20.5M Buy
+3,921,568
New +$16.1M 0.01% 603

Other funds holding IMMX

SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Janus Henderson Group's IMMX Position: Q1 2026 in Review

Janus Henderson Group increased its Immix Biopharma (IMMX) stake by 22% in Q1 2026, buying an estimated $6.47M and bringing the position to 4,802,002 shares worth $43.7M. The position accounts for 0.02% of the portfolio, ranked #440.

Janus Henderson Group first reported a position in IMMX in Q4 2025 and has held it in 2 quarters since. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

  • Janus Henderson Group held 4,802,002 shares of Immix Biopharma worth $43.7M as of Q1 2026.
  • Janus Henderson Group bought 880,434 Immix Biopharma shares in Q1 2026, an estimated $6.47M.
  • Immix Biopharma made up 0.02% of Janus Henderson Group's portfolio in Q1 2026, its #440 holding.
  • Janus Henderson Group first reported a position in Immix Biopharma in Q4 2025 and has held it in 2 quarters since.
  • 77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.